PLEKHH3

Across TCGA pan-cancer cohorts, PLEKHH3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PLEKHH3 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PLEKHH3 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PLEKHH3 expression acts as an unfavorable survival marker, although some lineages such as LUAD and UCEC show a favorable association.

LUAD, PDAC, and LSCC are the cancer types where PLEKHH3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.959	0.626	.001	53	view →
PDAC	DFS	Tertile	II,III,IV	0.369	0.677	.037	6	view →
LSCC	DFS	Median	II,III,IV	0.843	0.999	.033	2	view →
UCEC	OS	Median	All	1.000	0.830	.028	2	view →
HNSC	OS	Median	II,III,IV	0.654	0.910	.031	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PLEKHH3–LUAD (OS)

Open the LUAD breakdown →